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Abstract: In Western countries, venous thromboembolism (VTE) is a widespread and serious 
disorder, with hospital admission rates that appear to be increasing. Current anticoagulant 
therapies available for the prevention and treatment of VTE have several drawbacks that make 
them either difﬁ  cult to manage effectively, due to a need for careful monitoring to control 
coagulation, or, in the case of parenterally administered agents, inconvenient for long-term use. 
To address some of these issues, new anticoagulants are in clinical development that can be 
orally administered and directly target speciﬁ  c factors in the coagulation cascade. This article 
reviews the rationale behind development of these novel agents and provides a critical appraisal 
of their clinical potential. In addition, the impact that the introduction of such agents into clinical 
practice would have is discussed from the patient perspective.
Keywords: antithrombotic agents, venous thromboembolism, Factor Xa, thrombin
The history of antithrombotics
Anticoagulants are recommended for the prevention and treatment of venous 
thromboembolism (VTE), and the prevention of thromboembolic events in patients 
with chronic conditions such as atrial ﬁ  brillation (AF) (Buller et al 2004; Geerts et al 
2008), or in patients with mechanical heart valves. For the prevention of VTE, the 
American College of Chest Physician (ACCP) guidelines recommend that extended 
thromboprophylaxis should be given to patients for up to 35 days (grade 1A) following 
total hip replacement (THR) and for at least 10 days after total knee replacement 
(TKR) (grade 1A) (Geerts et al 2008). Currently available anticoagulants comprise 
the heparins – unfractionated heparin (UFH) and the low molecular weight heparins 
(LMWHs), eg enoxaparin, tinzaparin, dalteparin – the vitamin K antagonists (VKAs), 
including warfarin, and the synthetic pentasaccharide fondaparinux. Although effective, 
these agents have signiﬁ  cant limitations (Table 1).
UFH, developed more than 60 years ago (Hirsh et al 2007), requires parenteral 
administration, making it inconvenient for use outside the hospital setting. It also 
requires coagulation monitoring and is associated with heparin-induced thrombocyto-
penia (HIT) and osteopenia (Hirsh et al 2001). The LMWHs, developed in the 1980s, 
overcame some of the drawbacks associated with UFH: they do not require monitoring 
and have a substantially lower risk of HIT compared with UFH (Warkentin et al 1995). 
However, LMWHs are administered by subcutaneous injection, and accumulation can 
occur in patients with renal impairment (Hirsh et al 2004).
VKAs have been in use in humans for more than 50 years and are currently the 
only oral anticoagulants available. The utility of VKAs is limited by the difﬁ  culty of 
managing them, the requirement of frequent monitoring and the necessity for dose 
adjustment to limit the adverse consequences of a narrow therapeutic window, multiple 
food and drug interactions, and variable pharmacology. These qualities, in addition to Vascular Health and Risk Management 2008:4(6) 1374
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the bleeding risk and other adverse effects, may contribute 
to the frequent underuse of warfarin, especially in elderly 
patients (Ansell et al 2004; Dantas et al 2004). In addition, 
VKAs have a slow onset of action. This can be a particular 
problem in VTE treatment, when the patient is at immediate 
risk of thrombus growth. In this situation, bridging therapy 
initiated with parenteral anticoagulants with a fast onset of 
action is necessary.
Fondaparinux, approved for use in the US in 2001 and 
Europe in 2002, has been shown to be relatively safe and 
effective in a variety of indications. However, like the 
heparins, it requires parenteral administration, which can be 
inconvenient when long-term use is necessary. Moreover, 
fondaparinux can also accumulate in patients with renal 
impairment due to renal elimination kinetics. Clearly, there 
is an unmet need for a convenient, safe antithrombotic agent 
that can be administered orally and does not require frequent 
monitoring or dose adjustment.
Current focus of antithrombotic 
development
The rationale behind the development of antithrombotics 
is based on an understanding of the coagulation cascade 
(Figure 1). The coagulation cascade can be initiated via 
either the intrinsic or extrinsic pathways. Initiation of the 
intrinsic coagulation cascade occurs when prekallikrein, 
high-molecular-weight kininogen, Factor XI, and Factor XII 
are exposed to a negatively charged surface, eg, phospholipids 
of circulating lipoprotein particles or bacterial surfaces. This 
is termed the contact phase and results in the conversion 
of prekallikrein to kallikrein, which in turn catalyzes the 
activation of Factor XII to activated Factor XII (FXIIa). 
FXIIa promotes the activation of Factor XI to FXIa, causing 
the release of bradykinin from high-molecular-weight 
kininogen. Factor IX is a proenzyme that contains vitamin 
K-dependent γ-carboxyglutamate residues, whose serine 
protease activity is activated following Ca2+ binding to the 
γ-carboxyglutamate residues. In the presence of Ca2+, FXIa 
catalyzes the activation of Factor IX to FIXa. FIXa catalyzes 
the activation of Factor X to FXa, through interaction with 
the protein cofactor VIII (intrinsic tenase).
The extrinsic coagulation cascade is initiated following 
vascular injury by exposure of tissue factor (TF) to circulating 
plasma coagulation factors. TF and activated Factor VII 
(FVIIa; extrinsic tenase) catalyze the conversion of Factor 
X to FXa. The TF/FVIIa complex also catalyzes the activa-
tion of Factor IX of the intrinsic pathway, which in turn 
catalyzes the activation of Factor X. FXa, the point where 
the two coagulation cascades meet, catalyzes the activation 
of prothrombin (Factor II) to form thrombin (Factor IIa). 
The activation of thrombin occurs on the surface of activated 
platelets and requires formation of a prothrombinase com-
plex. This complex is composed of the platelet phospholipids, 
phosphatidylinositol and phosphatidylserine, Ca2+, Factors 
Va and Xa, and prothrombin. Thrombin catalyzes the conver-
sion of ﬁ  brinogen (Factor I) to ﬁ  brin (Factor Ia) and ﬁ  brin 
forms a mesh that, in conjunction with the platelets, plugs 
the break in the vessel wall. Thrombin also catalyzes the 
activation of Factor XIII, consequently stabilizing the ﬁ  brin 
network by forming crosslinks (Davie 1995).
Conventional therapies (ie VKAs, UFH, and LMWHs) 
act on multiple targets within the coagulation cascade 
(Hawkins 2004). VKAs inhibit the vitamin-K-dependent 
γ-carboxylation of the clotting factors prothrombin and 
Factors VII, IX and X (McBride 2005). UFH and LMWHs 
potentiate the inhibitory action of antithrombin on thrombin 
Table 1 Limitations of current anticoagulants
Anticoagulant Limitations Consequences
UFH Parenteral mode of administration Inconvenient for long-term use
Unpredictable anticoagulant effect due to unspeciﬁ  c binding Regular monitoring of aPTT required
Risk of HIT Monitoring of platelet count required
LMWH Parenteral mode of administration Inconvenient and expensive for long-term use
Risk of HIT Monitoring of platelet count required
VKAs Unpredictable anticoagulant effect 
Slow onset of action and narrow therapeutic window
Regular monitoring and dose adjustment required 
to ensure patients stay within target INR (usually 2–3)
Food and drug interactions Risk of adverse events (for example, bleeding)
Fondaparinux Parenteral mode of administration Inconvenient and expensive for long-term use
Abbreviations: UFH,  unfractionated heparin;  LMWH,  low-molecular-weight heparin;   VKAs,  vitamin K antagonists;  aPTT, activated partial thromboplastin time;  HIT,  heparin-induced 
thrombocytopenia; INR, international normalized ratio.Vascular Health and Risk Management 2008:4(6) 1375
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and FXa, and also induce the release of TF pathway inhibitor 
from endothelial cells, further enhancing their anticoagulant 
activity (Hirsh et al 2007). The unpredictable anticoagulation 
patterns sometimes observed with VKAs and UFH could in 
part be explained by their action on multiple factors, because 
each factor targeted has a different half-life. Furthermore, 
thrombin formation is individualized due to genetic factors 
that are still not fully understood. In addition, conventional 
therapies are unable to antagonize the effects of throm-
bin bound to the clot, even though clot-bound thrombin 
retains enzymatic activity. Because thrombin potentiates 
its own generation via feedback stimulation of FV, FVIII, 
and FIX, this creates the potential for therapeutic failure 
(McBride 2005).
In an attempt to render the effects of anticoagulants more 
predictable than the VKAs and UFH, recent research efforts 
have focused primarily on the direct inhibition of a single 
coagulation factor, namely thrombin and FXa – two serine 
proteases with key functions in the coagulation cascade 
(Ansell 2007). Thrombin is a procoagulant but also plays an 
important role in anticoagulation and anti-inﬂ  ammation via 
thrombin–thrombomodulin-mediated activation of protein C 
(Linder et al 1999). Thrombin also promotes inﬂ  ammation 
and cellular proliferation (Esmon et al 1993; Tarzami et al 
2006; Vesey et al 2005). The early direct thrombin inhibitors 
(DTIs) bivalirudin and argatroban, which provided proof of 
concept for direct thrombin inhibition, are still in use today. 
However, due to their specific pharmacokinetic and 
pharmacodynamic properties, they are used only in speciﬁ  c 
patient populations, eg in patients undergoing percutaneous 
coronary intervention or in patients with HIT. Ximelegatran 
(AstraZeneca) was the ﬁ  rst oral DTI developed and was 
a prodrug of the active-site-directed thrombin inhibitor, 
melagatran (Gustafsson et al 2001). Ximelagatran was shown 
to be effective for the prevention and treatment of VTE in 
several phase II and phase III clinical trials: METHRO III 
(Eriksson et al 2003b), EXPRESS (Eriksson et al 2003a), 
EXULT A and B (Colwell, Jr. et al 2003; Francis et al 2003), 
and THRIVE II and III (Fiessinger et al 2005; Schulman et al 
2003). Ximelagatran was also evaluated for the prevention 
of stroke and systemic embolism in patients with AF in the 
SPORTIF III and V trials (Albers et al 2005; Olsson 2003). 
Based on the results of phase III trials, ximelagatran was 
launched in Europe in 2004 for the prevention of VTE after 
major orthopaedic surgery. However, it was withdrawn in 
2006 due to concerns regarding liver toxicity and rebound 
cardiovascular effects. In the orthopedic development 
program, cardiovascular events and total mortality were 
signiﬁ  cantly increased in the ximelagatran group compared 
with the control groups. Because of liver toxicity concerns, 
the US Food and Drug Administration never approved 
ximelagatran.
Figure 1 The coagulation cascade.
Abbreviations: VKAs, vitamin K antagonists;   AT, antithrombin.
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FXa is another rational target for the development 
of antithrombotics. FXa promotes both coagulation and 
inﬂ  ammation, and is at the point where the intrinsic and 
extrinsic coagulation cascade pathways meet. Inhibition of 
FXa is potentially more effective than targeting downstream 
thrombin, because the amount of activated coagulation factor 
generated from its inactive precursor increases at each level 
of the cascade. FXa is the primary site of ampliﬁ  cation in 
the coagulation cascade: one molecule of FXa can facilitate 
the generation of more than 1000 thrombin molecules (Mann 
et al 2003). Proof of principal for pure FXa inhibition was 
provided by fondaparinux, which selectively but indirectly 
inhibits FXa by binding to antithrombin and potentiating its 
inhibition of FXa. Razaxaban (Bristol-Myers Squib) was one 
of the ﬁ  rst direct FXa inhibitors developed. The antithrom-
botic potential of razaxaban was investigated in a phase II 
VTE prevention study after TKR (Lassen et al 2003). Four 
doses of razaxaban (range 25–100 mg given twice daily 
[bid]) were evaluated. The study showed a highly signiﬁ  cant 
reduction of thromboembolic events with increased doses 
of razaxaban. However, the three higher dose arms of the 
study were stopped prematurely because of increased rates 
of major bleeding. Further development of razaxaban was 
halted and was replaced by development of another FXa 
inhibitor, apixaban.
There are several promising oral anticoagulants currently 
in clinical development, including the DTI dabigatran 
etexilate and the direct FXa inhibitors rivaroxaban and 
apixaban. This review will provide a critical appraisal of the 
clinical potential of these agents.
Dabigatran
Dabigatran (Boehringer Ingelheim) is a speciﬁ  c, competitive, 
and reversible DTI that is administered as the oral prodrug 
dabigatran etexilate (Eriksson et al 2004; Stangier et al 2005). 
Dabigatran is formed by the rapid esterase-catalyzed 
conversion of dabigatran etexilate via two intermediary 
prodrugs (Blech et al 2008). Dabigatran binds to the active 
site of thrombin (Ki 4.5 nM) by hydrophobic interaction 
(Hauel et al 2002), thereby inhibiting the cleavage of ﬁ  brino-
gen to ﬁ  brin, and blocking the ﬁ  nal step of the coagulation 
cascade, and thus thrombus formation. Dabigatran inhibits 
both free and ﬁ  brin-bound thrombin (Stangier et al 2007). 
The prodrug dabigatran etexilate is absorbed rapidly, but 
has low oral bioavailability (approximately 6.5%) (Stangier 
et al 2007). Peak plasma concentrations of dabigatran occur 
approximately 2 hours after administration, and steady-state 
conditions are reached within 3 days after multiple dosing. 
The average terminal elimination half-life of dabigatran is 
15 hours, protein binding is moderate (25%–30%), and the 
compound is cleared predominantly via the renal pathway 
(Stangier et al 2007) (Table 2).
The antithrombotic potential of dabigatran for VTE 
prevention following THR or TKR was investigated in a 
double-blind, randomized, phase II dose-ranging study, 
BISTRO II (Eriksson et al 2005a). The primary efﬁ  cacy 
outcome was the incidence of VTE (symptomatic, or 
asymptomatic, detected by venography) during 6–10 days 
of study drug. Of 1464 patients evaluable for the efﬁ  cacy 
analysis, VTE occurred in 28.5%, 17.4%, 13.1%, 16.6%, 
and 24.0% of patients receiving dabigatran etexilate 50, 
150, 225 mg bid, or 300 mg once daily (od), and enoxapa-
rin 40 mg od, respectively. A signiﬁ  cant dose-dependent 
decrease in VTE occurred with increasing doses of dabigatran 
etexilate (p   0.0001). Major bleeding was low with 50 mg 
bid dabigatran etexilate, relative to enoxaparin (0.3% and 
2.0%, respectively; p = 0.047), but was elevated relative to 
enoxaparin at higher daily doses (Table 3).
Based on the results of BISTRO II, dabigatran (220 mg 
or 150 mg od) was compared with enoxaparin 40 mg od, 
Table 2 Therapeutic target and pharmacologic properties of oral antithrombotic agents in clinical development
Drug Manufacturer Molecular 
weight
Therapeutic 
target
Half-life Time 
to Cmax
Bioavailability Mode 
of elimination
Dabigatran Boehringer Ingelheim 628 (dabigatran 
etexilate), 471 
(dabigatran)
Thrombin 
(Factor IIa)
14–17 h with multiple 
doses; 7–9 h with single 
doses
2 h Approximately 
6.5% in humans
Renal
Rivaroxaban Bayer HealthCare  AG 
and Johnson & Johnson 
Pharmaceutical Research and 
Development, L.L.C.
436 Factor Xa Approximately 9 h 
in healthy subjects; 
approximately 12 h in 
elderly subjects ( 75 yr)
2–4 h Approximately 
80% in humans
Renal/biliary-
fecal
Apixaban Bristol-Myers Squibb and 
Pﬁ  zer
460 Factor Xa Approximately 12 h; 
terminal half-life 8–15 h
3 h Chimps (51%); 
dogs (88%); 
rats (43%)
Renal/fecalVascular Health and Risk Management 2008:4(6) 1377
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for VTE prevention for 35 days in patients after THR in 
the phase III RE-NOVATE study (Eriksson et al 2007a). 
In this study, the primary endpoint of non-inferiority to 
enoxaparin was met; the primary outcome (deep vein 
thrombosis [DVT], pulmonary embolism [PE], and all-cause 
mortality) occurred in 8.6% and 6.0% of patients receiving 
150 and 220 mg oral dabigatran etexilate od, respectively, 
compared with 6.7% of patients receiving enoxaparin. The 
rate of major bleeding was 1.3% and 2.0% in the 150 and 
220 mg od dabigatran etexilate arms, respectively, compared 
with 1.6% in the enoxaparin group (Table 3).
The efﬁ  cacy and safety of dabigatran for VTE prevention 
after TKR was evaluated in two phase III studies: 
RE-MODEL (Eriksson et al 2006c) and RE-MOBILIZE 
(The RE-MOBILIZE Writing Committee 2008). In the 
RE-MODEL study, 2183 patients were randomized to 
receive dabigatran etexilate 150 or 220 mg od, or enoxaparin 
40 mg od for 6–10 days. The primary efﬁ  cacy outcome 
(a composite of total VTE and mortality) occurred in 37.7% 
of the enoxaparin group compared with 36.4% and 40.5% 
of the dabigatran 220 and 150 mg groups, respectively. The 
incidence of major bleeding was similar between the three 
groups. Overall, both doses of dabigatran were non-inferior 
to enoxaparin, with a similar safety proﬁ  le. However, in 
the RE-MOBILIZE study, non-inferiority of dabigatran to 
enoxaparin was not demonstrated. In this study, 2596 patients 
were randomized to either dabigatran 150 or 220 mg od or 
enoxaparin 30 mg bid for 12–15 days. The incidence of the 
primary outcome was 33.7%, 31.1% and 25.3%, respectively. 
The largest component of the primary outcome, distal DVT, 
occurred in 30.5% of patients receiving dabigatran 150 mg 
od, 27.6% of patients receiving dabigatran 220 mg od, and 
23.0% of patients receiving enoxaparin. The incidence of 
major bleeding events was 0.6% for both dabigatran 150 and 
220 mg and 1.4% for enoxaparin (Table 3).
In a pooled analysis of the RE-MODEL, RE-MOBILIZE, 
and RE-NOVATE studies (Caprini et al 2007), major VTE 
and VTE-related death occurred in 3.3% of the enoxaparin 
group versus 3.0% of the dabigatran etexilate 220 mg group 
and 3.8% of the dabigatran etexilate 150 mg group. Major 
bleeding events were infrequent, and occurred at similar 
rates across all groups: enoxaparin 1.4%, dabigatran etexilate 
220 mg 1.4%, and dabigatran etexilate 150 mg 1.1%.
In summary, dabigatran has demonstrated non-inferiority 
and a similar safety proﬁ  le to enoxaparin for VTE prevention 
after THR, and represents a viable, orally administered 
alternative to enoxaparin in this setting. The results for 
VTE prevention after TKR are less conclusive. Dabigatran 
demonstrated non-inferiority to enoxaparin in one phase III 
study but not in another, although it should be noted that 
different enoxaparin dosing regimens were used in each of 
these studies; bleeding rates with dabigatran were similar 
to enoxaparin in both studies. Based on the results of 
phase III studies, dabigatran has recently been approved in 
the European Union for the prevention of VTE following 
major orthopaedic surgery in adults.
Dabigatran is currently being investigated in three further 
phase III trials: RE-LY, a study comparing the efﬁ  cacy and 
safety of dabigatran with warfarin for the prevention of stroke 
and systemic embolism in patients with non-valvular AF; 
RE-COVER, a randomized study comparing the efﬁ  cacy and 
safety of dabigatran etexilate with warfarin for the treatment 
of acute symptomatic VTE, following initial treatment with 
a parenteral anticoagulant; and RE-MEDY, a randomized, 
active controlled study to evaluate the efﬁ  cacy and safety 
of oral dabigatran etexilate compared with warfarin, for the 
secondary prevention of VTE.
Rivaroxaban
Rivaroxaban (Bayer HealthCare AG and Johnson & Johnson 
Pharmaceutical Research and Development, L.L.C.) is 
a once-daily, oral, direct FXa inhibitor. It selectively 
and competitively binds to FXa (Ki 0.4 nM) with 1:1 
stoichiometry, blocking the interaction of FXa with its 
substrate prothrombin (Hirsh et al 2005). Rivaroxaban binds 
to the active site of FXa, its chlorothiophene moiety directed 
into the S1 pocket, and does not require highly basic groups 
like amidines for FXa afﬁ  nity (Roehrig et al 2005). Binding 
inhibits not only free FXa but also ﬁ  brin-bound FXa and 
prothrombinase activity (Graff et al 2007). Rivaroxaban has 
high bioavailability and a dual mode of elimination, with 
one-third of the dose excreted unchanged via the kidneys, 
and two-thirds metabolized by the liver (Weinz et al 2004). 
Maximum plasma levels of rivaroxaban occur 2–4 hours 
after oral administration and elimination of rivaroxaban 
from plasma occurs with a terminal half-life of 5–9 hours in 
young individuals, and 11–12 hours in the elderly (Kubitza 
et al 2005b; Kubitza et al 2007c) (Table 2).
Three phase IIb trials, ODIXa-HIP2 (Eriksson et al 2006a), 
ODIXa-KNEE (Turpie et al 2005), and ODIXa-OD-HIP 
(Eriksson et al 2006b), were initiated to investigate the 
antithrombotic potential of rivaroxaban for VTE prevention 
following major orthopaedic surgery (THR or TKR). 
The primary efﬁ  cacy outcome in these trials was the compos-
ite of any DVT, non-fatal PE, and all-cause mortality, and the 
primary safety outcome was major, post-operative bleeding. Vascular Health and Risk Management 2008:4(6) 1378
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These trials were designed to allow pooling of the results and 
had the same independent blinded adjudication committees. 
Subjects were randomized to receive various doses of oral 
rivaroxaban (administered bid in two studies and od in one 
study) or subcutaneous enoxaparin (30 or 40 mg) for 5–9 days 
after surgery. The results of the phase II bid studies showed 
that total daily doses of 5–20 mg rivaroxaban warranted 
further investigation, while the od study demonstrated that a 
10 mg once-daily dose of rivaroxaban provided the optimum 
balance between efﬁ  cacy and safety. Based on these ﬁ  ndings, 
a once-daily 10 mg dose of rivaroxaban was evaluated in 
phase III studies (Table 3).
The RECORD1 trial compared extended prophylaxis 
with rivaroxaban with extended enoxaparin after THR 
(Eriksson et al 2008). Patients received either oral rivaroxaban 
(10 mg od), started 6–8 hours after surgery for 35 ± 4 days, 
or subcutaneous enoxaparin (40 mg od), started the evening 
before surgery. In this study, the criteria for non-inferiority 
of rivaroxaban vs enoxaparin were met and testing for supe-
riority was performed. The primary efﬁ  cacy outcome (the 
composite of DVT, PE, and all-cause mortality) occurred in 
18/1595 (1.1%) of patients treated with rivaroxaban com-
pared with 58/1558 (3.7%) of those receiving enoxaparin 
(p   0.001), demonstrating a relative risk reduction (RRR) 
of 70%. The incidence of major bleeding was similar in both 
groups (6/2209 [0.3%] with rivaroxaban vs 2/2224 [0.1%] 
with enoxaparin) (Table 3).
In RECORD2, extended prophylaxis with rivaroxaban was 
compared with short-term enoxaparin followed by placebo 
for prevention of VTE after THR in 2509 patients (Kakkar 
et al 2008). Patients received subcutaneous enoxaparin 
40 mg od, beginning the evening before surgery, continuing for 
10–14 days (short-term prophylaxis), and followed by placebo 
until day 35 ± 4, or oral rivaroxaban 10 mg od beginning 
6–8 hours after surgery and continuing for 35 ± 4 days 
(extended prophylaxis). The primary efficacy outcome 
(composite of DVT, PE, and all-cause mortality) occurred in 
17/864 (2.0%) of patients given extended prophylaxis with 
rivaroxaban compared with 81/869 (9.3%) of patients given 
short-term prophylaxis with enoxaparin (p   0.0001), dem-
onstrating an RRR of 79%. The rate of major bleeding was 
low and similar in those receiving extended prophylaxis with 
rivaroxaban and short-term enoxaparin (1/1228 [0.1%] vs 
1/1229 [0.1%], respectively) (Table 3).
The RECORD3 trial evaluated oral rivaroxaban (10 mg od) 
compared with subcutaneous enoxaparin (40 mg od) for 
the prevention of VTE after TKR in 2531 patients (Lassen 
et al 2008). The primary efﬁ  cacy outcome (the composite 
of DVT, PE, and all-cause mortality) occurred in 79/824 
(9.6%) of patients receiving rivaroxaban compared with 
166/878 (18.9%) of those receiving enoxaparin (p   0.001), 
demonstrating an RRR of 49%. Major bleeding occurred in 
7/1220 (0.6%) administered rivaroxaban and 6/1239 (0.5%) of 
patients administered enoxaparin (p = 0.77) (Table 3).
RECORD4 compared once-daily oral rivaroxaban 
(10 mg) with twice-daily subcutaneous enoxaparin (30 mg) 
for VTE prophylaxis after TKR in 3148 randomized patients 
(Turpie et al 2008). The primary efﬁ  cacy outcome was the 
same as for RECORD3 and occurred in signiﬁ  cantly fewer 
patients in the rivaroxaban group. The rate of major bleeding 
was similar in the rivaroxaban and enoxaparin groups.
Rivaroxaban was also evaluated for VTE treatment 
in the phase II EINSTEIN-DVT (Buller et al 2008b) and 
ODIXa-DVT (Agnelli et al 2007a) trials. In these dose-
ranging studies, both od and bid rivaroxaban dosing had 
similar efﬁ  cacy to standard enoxaparin. In addition, a low 
rate of bleeding was observed with all rivaroxaban doses, 
suggesting that long-term treatment with rivaroxaban could 
be possible (Table 3). In the ODIXa-DVT study, the doses 
of rivaroxaban selected for evaluation (20–60 mg total 
daily doses) were based on pharmacokinetic and pharma-
codynamic analyses, as well as results of VTE prevention 
trials in which a 10 mg od dose appeared to be optimal – for 
treatment of established thrombosis, a minimum of two 
times the prophylactic dose was considered appropriate. 
In combination with results of the EINSTEIN-DVT study, 
where 20–40 mg od doses of rivaroxaban were evaluated, 
the lowest (20 mg/day) dose of rivaroxaban was chosen for 
evaluation in phase III clinical trials.
In summary, extended prophylaxis with rivaroxaban 
not only demonstrated non-inferiority, but was signiﬁ  cantly 
more effective than both extended prophylaxis and short-term 
prophylaxis with enoxaparin after THR. Rivaroxaban was also 
superior to enoxaparin for the prevention of VTE after TKR. 
Bleeding rates with rivaroxaban were similar to enoxaparin 
in each of the three studies, even in the RECORD2 study 
where extended prophylaxis with rivaroxaban was compared 
with short-term prophylaxis with enoxaparin. Based on these 
promising results, rivaroxaban represents a viable, oral alter-
native to enoxaparin for prevention of VTE following major 
orthopaedic surgery.
Other phase III trials with rivaroxaban are currently 
underway. Rivaroxaban is being evaluated for VTE treatment 
in a phase III study of patients with acute symptomatic DVT 
(EINSTEIN-DVT evaluation) or acute symptomatic PE 
(EINSTEIN-PE evaluation), and for long-term prevention Vascular Health and Risk Management 2008:4(6) 1381
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of recurrent symptomatic VTE in patients with symptomatic 
DVT or PE (EINSTEIN-extension study). A phase III study 
of rivaroxaban for VTE prophylaxis in medically ill patients 
has also been initiated (MEGELLAN), and rivaroxaban is 
being compared with warfarin for stroke prevention in patients 
with AF (ROCKET AF). Finally, rivaroxaban in combina-
tion with aspirin alone or with aspirin and a thienopyridine is 
being investigated in a phase II study of subjects with acute 
coronary syndromes (ATLAS ACS TIMI 46 Trial).
Apixaban
Apixaban (Bristol-Myers Squib), a follow-up compound to 
razaxaban, is a selective, reversible, direct FXa inhibitor. 
Apixaban has a Ki for FXa of 0.8 nM, and it inhibits 
prothrombinase activity as well as free FXa (Weitz 2006). 
Apixaban demonstrates relatively high oral bioavailability 
in animal models (51% in chimps; 88% in dogs; 43% in 
rats) (He et al 2006) and has a half-life of approximately 
12 hours in humans (Frost et al 2007). Maximum plasma 
levels of apixaban are reached approximately 3 hours after 
administration. Apixaban is cleared through renal (approxi-
mately 25%) and fecal routes (approximately 70%) (Lassen 
et al 2006) (Table 2).
The antithrombotic potential of apixaban, given od or 
bid, was investigated in a phase II trial in patients who had 
undergone TKR (Lassen et al 2007). The incidence of the 
primary efﬁ  cacy outcome (composite of VTE and all-cause 
mortality during administration) decreased with increasing 
apixaban dose versus comparators (enoxaparin 30 mg bid 
or warfarin [international normalized ratio (INR) 1.8–3.0]), 
although the trend was not signiﬁ  cant (p = 0.09 with od/bid 
apixaban regimens combined, p = 0.19 for od and p = 0.13 for 
bid dosing). Overall, total VTE rates were slightly lower in the 
bid than in the od apixaban arms. A signiﬁ  cant dose-related 
increase in the incidence of total adjudicated bleeding events 
was noted in the od (p = 0.01) and bid (p = 0.02) apixaban 
groups; there was no difference between od and bid regimens. 
Because, at each total dose of apixaban, there were lower 
point estimates for the primary outcome with bid versus od 
dosing, bid dosing was established as the preferred regimen 
to be tested in a comprehensive phase III program. Apixaban 
was also evaluated for VTE treatment in the phase II 
BOTICELLI trial (Buller et al 2008a). The primary efﬁ  cacy 
outcome was the composite of symptomatic recurrent VTE 
and deterioration of the thrombotic burden. The primary 
safety outcome was the composite of major and clinically 
relevant non-major bleeding. Primary efﬁ  cacy outcome 
rates were 6.0% for patients in the 5 mg bid apixaban group, 
5.6% for patients in the 10 mg bid group, and 2.6% in the 
20 mg od group compared with 4.2% for the control group 
(LMWH or fondaparinux followed by VKA). Rates of major 
bleeding were 0.8% (5 mg bid), 0.0% (10 mg bid), 1.6% 
20 mg od), and 0.0% (control) (Table 3).
Apixaban is currently being evaluated in phase III 
VTE prevention studies following TKR (ADVANCE-1, 
2.5 mg oral apixaban bid vs 30 mg subcutaneous enoxaparin 
bid; ADVANCE-2, 2.5 mg oral apixaban bid vs 40 mg 
subcutaneous enoxaparin od), THR (ADVANCE-3, 2.5 mg 
oral apixaban bid vs 40 mg subcutaneous enoxaparin od), 
and in acutely medically ill patients. Apixaban is also being 
compared with acetylsalicylic acid (ASA) in a phase III 
study for stroke prevention in AF (AVERROES) and with 
warfarin for prevention of stroke and systemic embolism in 
subjects with non-valvular AF (ARISTOTLE). A phase II, 
placebo-controlled, dose-ranging study to evaluate the safety 
and efﬁ  cacy of apixaban in patients with a recent ACS is 
also ongoing.
In summary, although apixaban is at an earlier stage 
of development than either dabigatran or rivaroxaban, it 
has demonstrated promising safety and efﬁ  cacy compared 
with the standard of care in phase II clinical trials for VTE 
prevention and treatment. However, based on the phase II 
dose-ﬁ  nding studies, bid rather than od apixaban dosing 
has been selected for further investigation in phase III VTE 
prevention trials. Dabigatran and rivaroxaban by comparison 
are administered od in this indication.
Other oral antithrombotics 
in clinical development
Numerous other oral antithrombotic agents that directly target 
FXa are currently in early clinical development (phase I or 
phase II). Betrixaban (Portola) is a compound with a Ki for 
FXa of 0.117 nM, bioavailability of 47%, and a half-life of 
19 hours. In animal models, betrixaban has demonstrated 
antithrombotic activity (Abe et al 2006) and, in a phase I 
dose-escalation study in 64 subjects, betrixaban displayed 
a long half-life, suggesting od dosing may be feasible. 
A phase II study to evaluate the efﬁ  cacy and safety of 
betrixaban for prevention of VTE is underway.
The compound DU-176b (Daiichi Sankyo) has a Ki for 
FXa of 0.56 nM and a 10,000-fold higher selectivity for 
FXa than for thrombin (Morishima et al 2004). DU-176b 
has also demonstrated promising antithrombotic potential 
in both venous and arterial models of thrombosis in rats 
(Eriksson et al 2005b). In a phase I study in healthy subjects 
(n = 12), DU-176b demonstrated a signiﬁ  cant reduction in Vascular Health and Risk Management 2008:4(6) 1382
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thrombus formation at both venous and arterial rheologies, 
up to 5 hours post-dose (Zafar et al 2007). Phase IIb studies 
of DU-176b in VTE prevention, stroke prevention in 
patients with AF, and in patients with ACS are planned or 
have been initiated.
YM150 (Astellas) is a compound that has a Ki for FXa 
of 31 nM, and inhibits activation of prothrombin induced 
by prothrombinase, free FXa, and whole-blood clots 
(Iwatsuki et al 2006). Proof of concept was demonstrated 
in a phase IIa dose-escalation study to assess the efﬁ  cacy 
and safety of YM150 for VTE prevention after THR 
(Eriksson et al 2007b). Patients (n = 174) undergoing hip 
replacement surgery were randomized to receive oral od 
YM150 (3–60 mg) or enoxaparin 40 mg od for 7–10 days. 
The primary outcome (major and/or clinically relevant non-
major bleeding) occurred in 2.9% and 5.7% of the 3 and 10 
mg YM150 dose groups, respectively. Of 147 patients with 
an evaluable venogram (84%), VTE (DVT/PE) occurred 
in 51.9%, 38.7%, 22.6%, and 18.5% of patients in the 
3, 10, 30, and 60 mg YM150 dose groups, respectively. 
A signiﬁ  cant YM150 dose-related trend in VTE incidence 
was demonstrated (p = 0.006). VTE occurred in 38.7 % of 
patients receiving enoxaparin.
LY-517717 (Eli Lilly) is an FXa inhibitor with 
1000-fold greater selectivity for FXa than related serine 
proteases. In preclinical studies, LY-517717 was shown 
to have a Ki of 4.6 to 6.6 nM and an oral bioavailability 
of 25%–82% (Turpie 2007). LY-517717 has a half-life 
of approximately 25 hours in humans, potentially mak-
ing it suitable for od dosing. In a phase II, non-inferiority 
study, LY-517717 has been compared with enoxaparin for 
VTE prevention in patients (n = 511) undergoing THR or 
TKR. Participants were randomized to receive one of six 
od doses of LY-517717 (starting 6–8 hours after wound 
closure) or od enoxaparin 40 mg (starting the evening 
before surgery). The primary efﬁ  cacy endpoint was DVT 
on mandatory bilateral venography within 12 hours of 
the last dose of study drug or objectively confirmed 
symptomatic VTE before day 30. Administration of 
LY-517717 resulted in a dose-dependent decrease in the 
incidence of thromboembolic events (p = 0.0001). The 
incidences of VTE were 19%, 19%, and 16% with 100, 
125, and 150 mg of LY-517717, respectively, compared 
with 21% with enoxaparin. These doses were non-inferior 
to enoxaparin with respect to the primary efﬁ  cacy endpoint. 
Bleeding events were similar in all study arms (100 mg: 
0.9%; 125 mg: 0.0%; 150 mg: 1.0%; and enoxaparin: 2.2%) 
(Agnelli et al 2007b).
A further oral, direct FXa inhibitor, PD 0348292 (Pﬁ  zer), 
is currently being evaluated for efﬁ  cacy and safety in the 
prevention of VTE following elective TKR in a phase IIb 
randomized, multicenter, dose-ranging study.
Patients’ perspectives
Patient non-compliance to anticoagulation therapy is 
common in clinical practice (McBride et al 2007). Patients 
receiving VKAs, eg, warfarin, require frequent monitoring 
and dose adjustments to achieve the desired therapeutic 
range (target INR usually 2–3). If the INR is out of the 
target range, bleeding and other adverse events may occur 
(Ansell et al 2001; Gurwitz et al 2007). The multiple food 
and drug interactions associated with VKAs also mean 
patients have to endure dietary restrictions, and discontinu-
ation of other medications may be necessary for effective 
anticoagulation to be achieved. A combination of these 
factors can potentially result in patients stopping their 
therapy, or becoming anxious about potential side-effects. 
Frequent dose adjustments or complex dosing regimens can 
be confusing (Hixson-Wallace et al 2001), particularly for 
elderly patients, where non-compliance can be a particular 
problem (Gurwitz et al 1992).
Patients receiving chronic warfarin therapy who have poor 
anticoagulation control (usually expressed as time in range) 
are at increased risk for adverse events (Oake et al 2007). In 
a recent, well-controlled clinical trial (ACTIVE-W), in which 
oral anticoagulation with a VKA was shown to be superior to 
the combination therapy of ASA and clopidogrel for preven-
tion of vascular events in patients with AF, patients receiving 
oral anticoagulation therapy had INR values in the therapeutic 
range (2–3) 63.8% of the time; below 2, 20.8% of the time; and 
above 3, 15.4% of the time (Connolly et al 2006). The quality 
of warfarin anticoagulation control is potentially associated 
with patient compliance, demographics, knowledge about 
therapy, and perceived impact on quality of life. In a study 
of 52 patients from two anticoagulation clinics in the US 
(Davis et al 2005), only 14% of patients demonstrated good 
anticoagulation control. Adequate compliance was reported 
by 50% of patients and was signiﬁ  cantly associated with 
good anticoagulation control (p = 0.01). Good knowledge of 
anticoagulation therapy was reported in 37% of the group and 
19% reported that warfarin negatively impacted their quality 
of life; however, these factors were not signiﬁ  cantly associ-
ated with anticoagulation control. These ﬁ  ndings highlight 
the importance of patient compliance for achieving good 
coagulation control with VKAs. However, the situation in 
general practice may be worse than described in the above Vascular Health and Risk Management 2008:4(6) 1383
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studies, because it has been shown that anticoagulation control 
in routine medical care is potentially of a lower quality than in 
controlled clinical trials or specialized anticoagulation clinics 
(Menzin et al 2005).
Although UFH, LMWHs, and fondaparinux are easier to 
manage than VKAs, they require parenteral administration, 
which is inconvenient for use outside the clinic. UFH has 
the added disadvantage of requiring coagulation monitoring 
and is also associated with HIT and osteoporosis. The 
requirement for monitoring during VKA and UFH therapy 
necessitates regular visits to the clinic and potential disruption 
to daily routine.
From a patient perspective, a preferred anticoagulant 
would have a convenient mode of administration and a high 
efﬁ  cacy-to-safety index, with freedom from hemorrhagic 
or non-hemorrhagic (HIT, skin reactions or osteoporosis) 
side-effects. Other desirable attributes would include a 
predictable dose response that allows dosing without the 
need for laboratory monitoring, a rapid onset of action so 
that parenteral bridging therapy is not necessary, and minimal 
interaction with other drugs or food.
The future availability of the novel antithrombotics 
described in this article could provide patients with anti-
coagulants possessing many of these attributes. These 
anticoagulants are administered either once or twice daily 
in a convenient oral form and have a rapid onset of action. 
Because they directly target one specific factor in the 
coagulation cascade, their pharmacology is likely to be 
more predictable, negating the need for monitoring. Close 
relationships between phamacokinetic and pharmacodynamic 
measurements have been demonstrated for dabigatran and 
rivaroxaban. Plasma concentrations of dabigatran correlate 
well with activated partial thromboplastin time and ecarin 
clotting time (Stangier et al 2007), and rivaroxaban plasma 
concentrations show a close correlation with FXa activity and 
prothrombin time. These ﬁ  ndings highlight the predictable 
pharmacology of dabigatran and rivaroxaban compared with 
the VKAs (Kubitza et al 2005a). In addition, it has been dem-
onstrated that dabigatran and rivaroxaban have no clinically 
relevant interaction with food (Kubitza et al 2006; Stangier 
et al 2007), and a low propensity for drug–drug interactions 
(Blech et al 2008; Kubitza et al 2006; Kubitza et al 2007a; 
Kubitza et al 2007b), although concomitant use of dabiga-
tran with ASA signiﬁ  cantly increases the risk of bleeding 
compared with dabigatran alone (Ezekowitz et al 2007). 
Drug–drug interactions and the effect of food on apixaban 
have not currently been reported. Phase III clinical trials 
of dabigatran and rivaroxaban for the prevention of VTE 
have also demonstrated that non-hemorrhagic side-effects 
are rare, and that the risk of bleeding is similar compared 
with enoxaparin (Eriksson et al 2007a; Eriksson et al 2008; 
Kakkar et al 2008; Lassen et al 2008; The RE-MOBILIZE 
Writing Committee 2008). Rivaroxaban and dabigatran are 
currently being evaluated in phase III trials for VTE treat-
ment, secondary VTE prevention, prevention of stroke in AF 
(rivaroxaban), and prevention of stroke and systemic embo-
lism in non-valvular AF (dabigatran). Phase III trials for the 
prevention of VTE, the prevention of stroke in AF, and the 
prevention of stroke and systemic embolism in non-valvular 
AF are ongoing for apixaban.
Conclusions
Despite their unpredictable pharmacologic proﬁ  le and associ-
ated risks, VKAs are still widely used anticoagulants. They 
can be administered orally, usually reducing the length of 
hospital stay. Although if managed well VKAs are highly 
effective, the need for frequent monitoring of the INR has a 
negative impact on their cost-effectiveness. In addition, non-
compliance with VKA therapy results in many patients not 
receiving optimal anticoagulation and increases the risk of 
uncontrolled bleeding. UFH, LMWHs and fondaparinux are 
much safer and easier to manage than VKAs but they require 
parenteral administration, making them less convenient for 
use outside the hospital. There is a signiﬁ  cant unmet need for 
a convenient, predictable anticoagulant that is both effective 
and safe for the prevention and treatment of thromboembolic 
disorders. Several novel oral anticoagulants have recently 
demonstrated efﬁ  cacy and safety at least equivalent to stan-
dard treatments in randomized phase III trials and are now 
in the advanced stages of clinical development. The predict-
able pharmacologic proﬁ  le and anticoagulant effect of these 
agents removes the need for monitoring, and the associated 
hospital costs and inconvenience to the patient. In addition, 
oral dosing means patients can receive anticoagulation 
therapy at home.
The introduction of these orally active, novel anticoagu-
lants is likely to result in an improvement in the prevention and 
treatment of thromboembolic disorders, and may overcome 
many of the concerns associated with currently available 
therapies. Because of their predictable pharmacology, these 
newer agents are also reliable and may be safer than established 
antithrombotic drugs.
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